Group Award for Leveraging Activities - 2001 FDA Science Forum

Board C03

MRI is rapidly emerging as an essential diagnostic tool for the evaluation of toxicology, pathophysiology and pathology at the pre-clinical levels. MRI techniques have distinct characteristics that complement more traditional toxicological/pathological evaluations of experimental animals. In addition to animal studies, MRI can provide a non-invasive method for gathering data on the internal texture, chemical composition, pH, temperature, function or structure of a wide range of materials, fixed tissues, and foods. MRI data has the potential to contribute significantly to the resolution of regulatory issues. Heretofore, an in-house MRI capability has not been available to FDA scientists.

The FDA has recently established a 2-Tesla research MRI facility at MOD I. The magnet and hardware were obtained from the NIH. Space for the MRI facility was identified at MOD I. CFSAN provided funds for transport of the 7,000-pound superconducting magnet and for building modifications needed to accommodate the magnet and instrumentation. CFSAN also provided funds to purchase and install a new console and data system. Installation of the new console was accomplished in August, 2000.

A number of non-animal projects are already under way or in the planning stages. The veterinary infrastructure necessary for animal studies is now under development. When complete, the facility will be capable of imaging animals ranging in size from rats to dogs and primates. Other technical improvements and pulse sequence implementation is also progressing. Sample images and data generated at the MRI facility will be presented.